Welcome to our dedicated page for Blade Air Mobility SEC filings (Ticker: BLDE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BLDE SEC filings page on Stock Titan provides access to the regulatory history of Blade Air Mobility, Inc., which has since changed its name to Strata Critical Medical, Inc. and now trades on Nasdaq under the symbol SRTA, as disclosed in a Form 8-K dated August 29, 2025. These filings document the company’s evolution from a technology-powered air mobility platform combining passenger and medical operations into a focused medical logistics business.
Among the key documents are multiple Current Reports on Form 8-K. One Form 8-K filed on August 5, 2025 furnishes a press release announcing financial results for the quarter ended June 30, 2025 under Item 2.02 (Results of Operations and Financial Condition). Another Form 8-K filed on August 1, 2025 describes an Equity Purchase Agreement under Item 1.01, outlining the terms under which a subsidiary of Joby Aviation agreed to acquire Blade’s Passenger business, including the structure of cash or stock consideration, earn-out provisions, and related non-compete and commercial arrangements.
A subsequent Form 8-K filed on August 29, 2025 reports the completion of the Passenger business sale, details the consideration received in Joby Aviation common stock and potential additional amounts, and explains the company’s name change to Strata Critical Medical, Inc. and ticker change to SRTA. That filing also discusses related agreements, such as a restrictive covenant agreement and a commercial agreement giving Joby a role in providing certain medical transport services, and notes amendments to the company’s charter and bylaws.
Later 8-K filings under the Strata Critical Medical name, such as those dated September 16, 2025 and November 10, 2025, describe material events including the acquisition of Keystone Perfusion Services, LLC and the release of quarterly financial results. Together, these filings show how the company has shifted toward mission critical logistics and medical services for hospitals and healthcare providers.
On Stock Titan, users can review these BLDE-linked filings with AI-powered summaries that highlight the main terms of material agreements, changes in corporate structure, and key financial disclosures. Real-time updates from EDGAR, along with structured access to Forms 8-K and other reports, help investors quickly understand how Blade’s historical regulatory record connects to the current Strata Critical Medical (SRTA) listing.
Strata Critical Medical, Inc. Chief Accounting Officer Amir Cohen reported routine share dispositions related to tax withholding on vested restricted stock units. On September 4, 2025 and September 10, 2025, the issuer withheld a total of 9,190 shares of Class A common stock to satisfy tax obligations. After these withholdings, Cohen directly owns 94,570 shares. This amended filing corrects an earlier Form 4 that had overstated his direct beneficial ownership by 5,483 shares due to an omitted tax-withholding entry.
Wunsch Scott M reported acquisition or exercise transactions in this Form 4 filing.
Strata Critical Medical, Inc. CEO Scott M. Wunsch received an equity award of 18,067 restricted stock units tied to the company’s Class A common stock. The RSUs were granted at no cash cost to him as part of his quarterly commission program.
All 18,067 RSUs vest on June 8, 2026, provided he continues serving the company, and will be settled in shares upon vesting. After this grant, he holds 587,874 shares directly and 382,987 shares indirectly through a limited liability company of which he is the sole member.
Strata Critical Medical, Inc. reported a Form 4 for officer Scott M. Wunsch, CEO of Trinity Air Medical. On March 8, 2026, 3,631 shares of Class A common stock were withheld by the company to cover tax obligations from restricted stock unit vesting, a non-market disposition. After this, Wunsch held 569,807 shares directly and 382,987 shares indirectly through a limited liability company of which he is the sole member.
Strata Critical Medical, Inc. Chief Accounting Officer Amir Cohen reported a routine tax-withholding transaction. The issuer withheld 2,433 shares of Class A common stock at $4.54 per share to satisfy taxes on vested restricted stock units, and Cohen now directly holds 179,384 shares.
Strata Critical Medical, Inc. director and Co-CEO/General Counsel Melissa M. Tomkiel reported a routine tax-related share disposition. On March 8, 2026, 29,372 shares of Class A common stock were withheld at $4.54 per share to satisfy tax obligations from vesting restricted stock units. This was not an open-market sale but shares retained by the company to cover taxes. After this withholding, Tomkiel directly holds 1,613,990 shares of Class A common stock, indicating the transaction affected only a small portion of her overall position.
Strata Critical Medical, Inc. director and Co-CEO/CFO William A. Heyburn reported a tax-related share disposition. On March 8, 2026, 31,314 shares of Class A common stock were withheld by the company to satisfy tax obligations tied to vesting restricted stock units, rather than sold on the open market. After this withholding, Heyburn directly holds 1,336,774 shares of Class A common stock.
Strata Critical Medical, Inc., formerly Blade Air Mobility, describes its transformation into a focused provider of time‑critical logistics and clinical services for the U.S. transplant and broader healthcare markets. The company now operates two segments, Logistics and Clinical, offering air and ground organ transport, organ placement, surgical recovery, perfusion, preservation and cardiac care services under the Trinity and Keystone brands.
Strata highlights an asset‑light aviation model supplemented by a limited owned aircraft fleet, extensive use of third‑party operators, and proprietary technology to coordinate complex transplant workflows. In 2025 it divested its legacy Passenger business and acquired Keystone Perfusion Services, concentrating on Medical Customers such as transplant centers, hospitals and Organ Procurement Organizations.
The filing emphasizes numerous risks, including continued net losses, integration and divestiture execution, dependence on donor organ availability and reimbursement, operational and aviation safety hazards, climate and geopolitical disruptions, regulatory and privacy obligations, credit‑facility covenants, competition from integrated and device‑based rivals, and the need to recruit and retain specialized clinical, logistics and management talent.
Strata Critical Medical reported very strong growth for Q4 2025, with revenue rising 83.5% year over year to $66.8 million. Logistics revenue, which reflects organic growth, increased 35.3% to $49.2 million, while new Clinical operations contributed $17.6 million following the Keystone acquisition.
Gross profit nearly doubled to $14.4 million and gross margin improved to 21.6%. The net loss from continuing operations narrowed to $5.4 million, but the company remained unprofitable on a GAAP basis. Non-GAAP Adjusted EBITDA jumped to $7.0 million from $1.1 million.
For full year 2025, revenue reached $197.1 million and Adjusted EBITDA was $14.1 million, both above the high end of guidance. Strata raised its 2026 outlook to revenue of $260–275 million and Adjusted EBITDA of $29–33 million, and now expects free cash flow before aircraft and engine acquisitions of $15–22 million.
Cohen Amir reported acquisition or exercise transactions in this Form 4 filing.
Strata Critical Medical, Inc. Chief Accounting Officer Amir Cohen received an equity award in the form of 64,191 Restricted Stock Units (RSUs) of Class A common stock, reported at a price of $0.00 per share. After this grant, his directly held stake increased to 181,817 shares.
The RSUs will be settled in common shares as they vest. According to the vesting schedule, 6.25% of the RSUs (rounded down to the nearest whole number) will vest every three months after March 8, 2026, with any remaining unvested RSUs vesting on March 8, 2030, as long as he continues serving the company.
Wunsch Scott M reported acquisition or exercise transactions in this Form 4 filing.
Strata Critical Medical, Inc. reported that Scott M. Wunsch, CEO of Trinity Air Medical, received a grant of 51,353 restricted stock units of Class A common stock at no cost. These RSUs vest 6.25% every three months after March 8, 2026, with remaining units vesting on March 8, 2030, contingent on continued service. Following this award, he holds 573,438 shares directly and 382,987 shares indirectly through a limited liability company of which he is the sole member.